ReviewGland surgery2021
Prediction of optimal debulking surgery in ovarian cancer.
Review in Gland surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Metformin Use and Mortality in Women with Ovarian Cancer: An Updated Meta-Analysis.International journal of clinical practice · 2022 · on this mapPooled it
- Frequency of optimal and sub-optimal fertility-sparing surgery in young women with ovarian cancer: A single-center observational cohort study.Pakistan journal of medical sciences · 2026Article
- The shifting paradigm of programmed cell death ligand 1 (PD-L1) in anaplastic thyroid carcinoma: from pathology to clinical practice.Virchows Archiv : an international journal of pathology · 2026Review
- A Narrative Review of Clinical and Molecular Criteria for the Selection of Poor Candidates for Optimal Cytoreduction in Epithelial Ovarian Cancer.Life (Basel, Switzerland) · 2025Review
- The Predictive Model of Suboptimal Primary Debulking Surgery among Women with Ovarian Cancer Using Pre-Operative Computerized Tomography, Tumor Markers and Comparison with the Intraoperative Findings: An Experience in Tertiary Care Hospital of Pakistan.Asian Pacific journal of cancer prevention : APJCP · 2025Observational
- Predicting Complete Cytoreduction with Preoperative [Diagnostics (Basel, Switzerland) · 2024Review
- A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia.Current oncology (Toronto, Ont.) · 2024Article
- Construction of a nomogram model for predicting the outcome of debulking surgery for ovarian cancer on the basis of clinical indicators.Frontiers in oncology · 2024Review
- The Association between Mediated Deprivation and Ovarian Cancer Survival among African American Women.Cancers · 2023Article
- Magnetic Microrobots as a Platform for Cell Clean Up.... International Conference on Manipulation Automation and Robotics at Small Scales (MARSS). International Conference on Manipulation Automation and Robotics at Small Scales · 2023Article
- Prognostic Significance of Preoperative NLR, MLR, and PLR Values in Predicting the Outcome of Primary Cytoreductive Surgery in Serous Epithelial Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Diffusion-Weighted Magnetic Resonance Imaging in Ovarian Cancer: Exploiting Strengths and Understanding Limitations.Journal of clinical medicine · 2022Review
- Article
- Development and External Validation of a Novel Model for Predicting Postsurgical Recurrence and Overall Survival After Cytoreductive R0 Resection of Epithelial Ovarian Cancer.Frontiers in oncology · 2022Article
- Role of Positron Emission Tomography/Computed Tomography in Epithelial Ovarian Cancer.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mainstay management of advanced ovarian cancer is maximal cytoreductive surgery followed by chemotherapy. Neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) are alternative treatments for patients with comorbidity, poor performance status, and predicted for suboptimal debulking surgery. It is the invariable principle in any situation that no residual disease after the completion of surgery is useful for patients with ovarian cancer. Therefore, the prediction of optimal debulking before the treatment of ovarian cancer is of utmost importance. Many studies have reported on the use of serum biomarkers, such as cancer antigen 125 (CA125) or human epididymis 4 (HE4), and imaging studies, such as computed tomography (CT), diffusion-weighted magnetic resonance imaging (DW-MRI), and positron emission tomography (PET)/CT, to identify adequate surgical candidates for primary debulking surgery (PDS). Laparoscopy has also been studied as a reliable tool for the prediction of optimal debulking. Here, we summarize a review of the related literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.